DESIGN OF RECOMBINANT IL-10-PRODUCING STRAINS WITH REGULATED EXPRESSION
Ключові слова:
interleukin-10, recombinant strains, inducible expression, probiotic vectors, cytokine delivery.Анотація
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that plays a key role in regulating immune responses and maintaining immune homeostasis. This study examines current approaches to the development of recombinant microbial strains capable of producing IL-10 using regulated expression systems and inducible promoters for potential biomedical applications.
Посилання
Next-generation probiotics for inflammatory bowel disease. / M. Pesce et al. International Journal of Molecular Sciences. 2022. Vol. 23, Art. 5466. URL: https://doi.org/10.3390/ijms23105466.
Lactococcus lactis as an interleukin delivery system for prophylaxis and treatment of inflammatory and autoimmune diseases. / G. M. Campos et al. Pharmaceutics. 2023. Vol. 15, no. 2. Art. 487. URL: https://doi.org/10.3390/pharmaceutics15020487.
Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. / L. G. Bermúdez-Humarán et al. Microbial Cell Factories. 2011. Vol. 10, Suppl. 1. Art. S4. URL: https://doi.org/10.1186/1475-2859-10-S1-S4.
A new Bifidobacteria Expression SysTem (BEST) to produce and deliver interleukin-10 in Bifidobacterium bifidum. / A. Mauras et al. Frontiers in Microbiology. 2018. Vol. 9, Art. 3075. URL: https://doi.org/10.3389/fmicb.2018.03075.
Optimization of the Lactococcus lactis nisin-controlled gene expression system NICE for industrial applications. / I. Mierau et al. Microbial Cell Factories. 2005. Vol. 4, no. 1. P. 16. URL: https://doi.org/10.1186/1475-2859-4-16.
In situ delivery of cytokines by genetically engineered Lactococcus lactis. / L. Steidler. Antonie van Leeuwenhoek. 2002. Vol. 82, no. 1-4. P. 323-331. URL: https://doi.org/10.1023/A:1020656220815.
Use of genetically engineered Lactococcus lactis delivering IL-10 in colon inflammation. / R. Martín et al. Human Vaccines & Immunotherapeutics. 2014. Vol. 10, no. 6. P. 1611-1619. URL: https://doi.org/10.4161/hv.28549.
Use of wild type or recombinant lactic acid bacteria as an alternative treatment for gastrointestinal inflammatory diseases. / R. D. O. Carvalho et al. Frontiers in Microbiology. 2017. Vol. 8, Art. 800. URL: https://doi.org/10.3389/fmicb.2017.00800.
Engineering lactococci and lactobacilli for human health. / L. G. Bermúdez-Humarán et al. Trends in Biotechnology. 2013. Vol. 31, no. 8. P. 459-472. URL: https://doi.org/10.1016/j.tibtech.2013.05.005.
Genetically modified lactic acid bacteria as mucosal delivery vectors for therapeutic proteins and DNA vaccines. / L. G. Bermúdez-Humarán et al. Microbial Cell Factories. 2013. Vol. 1, Art. 71. URL: https://doi.org/10.1186/1475-2859-12-71.
